Erasca (ERAS) hires oncology leader Charles Fuchs with 1.3M option grant
Rhea-AI Filing Summary
Erasca, Inc. appointed Charles S. Fuchs, M.D., M.P.H., age 66, as President, Research & Development effective August 10, 2026. He has more than three decades of oncology leadership across academia and biopharmaceutical companies, including senior roles at Genentech, Roche, Tubulis, Yale Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute. There are no related-party relationships or appointment arrangements disclosed.
Under an employment offer letter, Dr. Fuchs will receive an annual base salary of $570,000, a target bonus equal to 45% of base salary, and stock options to purchase 1,300,000 shares of common stock, vesting over four years. Of these, 1,278,520 options were granted under a newly adopted 2026 Employment Inducement Incentive Award Plan, with 6,200,000 shares reserved for awards. The options will have an exercise price equal to the closing price on the grant date. Dr. Fuchs is designated a Tier 1 Covered Employee under the company’s severance plan and has entered into the company’s standard indemnification agreement.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Annual base salary: $570,000
Target bonus percentage: 45%
Stock options granted: 1,300,000 shares
+3 more
6 metrics
Annual base salary
$570,000
Base salary for President, Research & Development under Employment Agreement
Target bonus percentage
45%
Annual target bonus as a percentage of base salary for Dr. Fuchs
Stock options granted
1,300,000 shares
Total stock option award to Dr. Fuchs, vesting over four years
Options under Inducement Plan
1,278,520 shares
Portion of Dr. Fuchs’ options granted under 2026 Employment Inducement Incentive Award Plan
Inducement Plan share reserve
6,200,000 shares
Shares of common stock reserved for issuance under the 2026 Employment Inducement Incentive Award Plan
Initial vesting cliff
25%
Portion of stock options vesting on first anniversary of start date
Key Terms
2026 Employment Inducement Incentive Award Plan, Nasdaq Listing Rules, stock appreciation rights, Tier 1 Covered Employee, +1 more
5 terms
2026 Employment Inducement Incentive Award Plan financial
"the Board adopted the Inducement Plan and reserved 6,200,000 shares"
Nasdaq Listing Rules regulatory
"The Inducement Plan was adopted without stockholder approval pursuant to the applicable Nasdaq Listing Rules"
Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.
stock appreciation rights financial
"The Inducement Plan provides for the grant of equity-based awards, including ... stock appreciation rights"
Stock appreciation rights (SARs) are a form of employee compensation that give the holder the right to receive the increase in a company's stock price over a set baseline, paid in cash or shares, without having to buy the stock. For investors, SARs matter because they can create future cash outflows or share dilution and signal how a company rewards and motivates executives — similar to giving a bonus tied directly to how well the company’s stock performs.
Tier 1 Covered Employee financial
"Dr. Fuchs was also named as a “Tier 1 Covered Employee” under the Company’s Severance"
change in control financial
"treatment of equity awards in the event of a “merger” or “change in control” as defined"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive role did Erasca (ERAS) create for Charles S. Fuchs?
Erasca appointed Charles S. Fuchs, M.D., M.P.H. as President, Research & Development effective August 10, 2026. He brings extensive oncology leadership experience from Genentech, Roche, Yale Cancer Center, and Dana-Farber Cancer Institute.
What is the compensation package for Erasca’s new R&D President (ERAS)?
Dr. Fuchs will receive an annual base salary of $570,000, a target annual bonus of 45% of base salary, and stock options to purchase 1,300,000 shares of Erasca common stock, vesting over four years.
How many Erasca (ERAS) stock options were granted to Dr. Fuchs and how do they vest?
Dr. Fuchs received stock options for 1,300,000 shares. 25% vest on the first anniversary of his start date, with the remaining options vesting in equal monthly installments thereafter, subject to continued employment or service.
What is Erasca’s 2026 Employment Inducement Incentive Award Plan (ERAS)?
Effective August 10, 2026, Erasca’s board adopted the 2026 Employment Inducement Incentive Award Plan, reserving 6,200,000 shares for equity awards. It was adopted without stockholder approval pursuant to applicable Nasdaq Listing Rules.
How many of Dr. Fuchs’ options are issued under Erasca’s Inducement Plan (ERAS)?
Of Dr. Fuchs’ 1,300,000 stock options, 1,278,520 are granted under the 2026 Employment Inducement Incentive Award Plan, with the remainder issued under Erasca’s 2021 Incentive Award Plan.